Paul Bolno, Wave Life Sciences CEO (via Twitter)
March 29, 2021 04:53 PM EDTUpdated March 29, 08:46 PM
R&D

Wave crash­es — again — as 2 more drugs go down to de­feat, this time for Hunt­ing­ton's

John Carroll

Editor & Founder

Just sev­en days ago Roche threw in the tow­el on their an­ti­sense drug for Hunt­ing­ton’s. Now we’re learn­ing that a close­ly-watched an­ti­sense oligonu­cleotide pro­gram …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

J&J takes 340B fight with fed­er­al gov­ern­ment to court

Dan­ish biotech Gubra touts ear­ly weight loss da­ta in hot amylin field

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

Ex­clu­sive: Flag­ship names two CEO-part­ners to lead Va­lo Health, Apri­ori Bio

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times